白癜风各民族医药学病名规范的专家共识

2021-07-30 中国民族医药学会皮肤科分会 中国民族医药杂志

各民族医药学古典医籍中,有大量关于“白癜风”的论述,但记载病名较为繁杂,不统一,不利于白癜风的研究。为了进一步促进白癜风研究和治疗,在前期大量文献研究基础上,筛选出中医学、维医

中文标题:

白癜风各民族医药学病名规范的专家共识

发布日期:

2021-07-30

简要介绍:

各民族医药学古典医籍中,有大量关于“白癜风”的论述,但记载病名较为繁杂,不统一,不利于白癜风的研究。为了进一步促进白癜风研究和治疗,在前期大量文献研究基础上,筛选出中医学、维医学、藏医学、蒙医学中与现代医学中的“白癜风”论述相似的病名,中国民族医药学会皮肤科分会组织专家,对民族医学白癜风病名进行规范,并形成共识。

相关资料下载:
[AttachmentFileName(sort=1, fileName=白癜风各民族医药学病名规范的专家共识.pdf)] GetToolGuiderByIdResponse(projectId=1, id=282b91c0022081e0, title=白癜风各民族医药学病名规范的专家共识, enTitle=, guiderFrom=中国民族医药杂志, authorId=0, author=, summary=各民族医药学古典医籍中,有大量关于“白癜风”的论述,但记载病名较为繁杂,不统一,不利于白癜风的研究。为了进一步促进白癜风研究和治疗,在前期大量文献研究基础上,筛选出中医学、维医, cover=https://img.medsci.cn/20211015/1634310178770_5579292.jpg, journalId=0, articlesId=null, associationId=2010, associationName=中国民族医药学会皮肤科分会, associationIntro=中国民族医药学会皮肤科分会, copyright=0, guiderPublishedTime=Fri Jul 30 00:00:00 CST 2021, originalUrl=, linkOutUrl=, content=<p><span style="color: #373737;">各民族医药学古典医籍中,有大量关于&ldquo;白癜风&rdquo;的论述,但记载病名较为繁杂,不统一,不利于白癜风的研究。为了进一步促进白癜风研究和治疗,在前期大量文献研究基础上,筛选出中医学、维医学、藏医学、蒙医学中与现代医学中的&ldquo;白癜风&rdquo;论述相似的病名,中国民族医药学会皮肤科分会组织专家,对民族医学白癜风病名进行规范,并形成共识。</span></p>, tagList=[TagDto(tagId=14834, tagName=白癜风)], categoryList=[CategoryDto(categoryId=39, categoryName=皮肤与性病, tenant=100), CategoryDto(categoryId=85, categoryName=指南&解读, tenant=100), CategoryDto(categoryId=21100, categoryName=达仁堂循证e学界, tenant=100)], articleKeywordId=0, articleKeyword=, articleKeywordNum=6, guiderKeywordId=14834, guiderKeyword=白癜风, guiderKeywordNum=6, haveAttachments=1, attachmentList=null, guiderType=0, guiderArea=共识, guiderLanguage=0, guiderRegion=3, opened=0, paymentType=, paymentAmount=10, recommend=0, recommendEndTime=null, sticky=0, stickyEndTime=null, allHits=3823, appHits=29, showAppHits=0, pcHits=1540, showPcHits=3794, likes=0, shares=1, comments=4, approvalStatus=1, publishedTime=Fri Oct 15 23:31:43 CST 2021, publishedTimeString=2021-07-30, pcVisible=1, appVisible=1, editorId=5579292, editor=FUNNYMAN, waterMark=0, formatted=0, memberCards=[], isPrivilege=0, deleted=0, version=3, createdBy=null, createdName=FUNNYMAN, createdTime=Fri Oct 15 23:05:56 CST 2021, updatedBy=5579292, updatedName=FUNNYMAN, updatedTime=Thu Jan 04 03:21:44 CST 2024, courseDetails=[], otherVersionGuiders=[], isGuiderMember=false, ipAttribution=, attachmentFileNameList=[AttachmentFileName(sort=1, fileName=白癜风各民族医药学病名规范的专家共识.pdf)])
白癜风各民族医药学病名规范的专家共识.pdf
下载请点击:
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1193552, encodeId=3de5119355248, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a86404305, createdName=ms4000000371205981, createdTime=Tue Feb 15 11:23:38 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188965, encodeId=c4aa118896554, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoroJymFHqlXuuAPk7Pm94ibicqFoZmF4t2mgQMDjZRESy379icJPOJa5JZAyF68CcvDbeG5ibnuSxI9A/132, createdBy=7ab02549644, createdName=李松岩啊, createdTime=Fri Jan 28 22:44:56 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060936, encodeId=7ad31060936bb, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:11:34 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060922, encodeId=65d510609223b, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:01:22 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-02-15 ms4000000371205981

    谢谢分享

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=1193552, encodeId=3de5119355248, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a86404305, createdName=ms4000000371205981, createdTime=Tue Feb 15 11:23:38 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188965, encodeId=c4aa118896554, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoroJymFHqlXuuAPk7Pm94ibicqFoZmF4t2mgQMDjZRESy379icJPOJa5JZAyF68CcvDbeG5ibnuSxI9A/132, createdBy=7ab02549644, createdName=李松岩啊, createdTime=Fri Jan 28 22:44:56 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060936, encodeId=7ad31060936bb, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:11:34 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060922, encodeId=65d510609223b, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:01:22 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2022-01-28 李松岩啊

    谢谢分享

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=1193552, encodeId=3de5119355248, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a86404305, createdName=ms4000000371205981, createdTime=Tue Feb 15 11:23:38 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188965, encodeId=c4aa118896554, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoroJymFHqlXuuAPk7Pm94ibicqFoZmF4t2mgQMDjZRESy379icJPOJa5JZAyF68CcvDbeG5ibnuSxI9A/132, createdBy=7ab02549644, createdName=李松岩啊, createdTime=Fri Jan 28 22:44:56 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060936, encodeId=7ad31060936bb, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:11:34 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060922, encodeId=65d510609223b, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:01:22 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 1207866fm50(暂无昵称)

    谢谢分享

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1193552, encodeId=3de5119355248, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=87a86404305, createdName=ms4000000371205981, createdTime=Tue Feb 15 11:23:38 CST 2022, time=2022-02-15, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1188965, encodeId=c4aa118896554, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=46, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=http://thirdwx.qlogo.cn/mmopen/vi_32/DYAIOgq83eoroJymFHqlXuuAPk7Pm94ibicqFoZmF4t2mgQMDjZRESy379icJPOJa5JZAyF68CcvDbeG5ibnuSxI9A/132, createdBy=7ab02549644, createdName=李松岩啊, createdTime=Fri Jan 28 22:44:56 CST 2022, time=2022-01-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060936, encodeId=7ad31060936bb, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=101, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:11:34 CST 2021, time=2021-10-16, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1060922, encodeId=65d510609223b, content=谢谢分享, beContent=null, objectType=guider, channel=null, level=null, likeNumber=91, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=644b2182796, createdName=1207866fm50(暂无昵称), createdTime=Sat Oct 16 08:01:22 CST 2021, time=2021-10-16, status=1, ipAttribution=)]
    2021-10-16 1207866fm50(暂无昵称)

    谢谢分享

    0

拓展阅读

白癜风诊疗共识(2014版)

中国中西医结合学会皮肤性病专业委员会 · 2014-01-01

白癜风中医治疗专家共识

暂未更新 · 2017-02-20

白癜风诊疗共识(2018版)

中国中西医结合学会皮肤性病专业委员会 · 2018-04-30

白癜风诊疗共识(2021版)

中国中西医结合学会皮肤性病专业委员会 · 2021-02-28

2021 BAD指南:白癜风患者的管理

英国皮肤科医师协会(BAD,British Association of Dermatologists) · 2021-06-23

2022 S1 指南:白癜风的诊断和治疗

德国皮肤病学会 (DDG) · 2022-03-04